# US 7,745,154 B2 · Preventives/remedies for myeloma tumor and method of diagnosing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,154 B2
- Document ID: US7745154B2
- Status: Granted
- Kind: B2
- Application number: 10/508,150
- Filed: 2003-03-19
- Published: 2005-11-10
- Granted: 2010-06-29
- Earliest claimed: 2002-03-19
- Assignees: Kowa Company, Ltd.
- Inventors: Yukihiko Saeki; Hideyuki Kobayashi; Yuichiro Tabunoki
- Web page: https://patentgrep.com/patent/US7745154B2

## CPC

- G01N 33/57585: {involving compounds identifiable in body fluids}
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 2333/52: Assays involving cytokines
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory or inhibitory effect; as well as a diagnostic kit for a myeloma tumor, characterized by including a reagent for measuring blood osteopontin level, and a diagnostic method.

## Claims

### Claim 1

A method for identifying a compound that reduces the severity of myeloma comprising:
contacting cells which produce osteopontin with a test compound and determining the amount of osteopontin produced in the presence of said test compound compared to the amount of osteopontin produced by the cells in the absence of said test compound,
selecting a test compound which reduces the amount of osteopontin produced by said cells, and
contacting said test compound, which reduces the amount of osteopontin produced, with myeloma tumor cells, and
selecting a test compound which reduces the severity of myeloma.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cells which produce osteopontin are B-cells or a B-cell line.

### Claim 3 (depends on 1)

The method of claim 1, which is an in vitro method.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ability of the test compound to reduce osteopontin production is determined by ELISA.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ability of the test compound to reduce osteopontin production is determined by an immunological technique.

### Claim 6 (depends on 1)

The method of claim 1, wherein the ability of the test compound to reduce osteopontin production is determined by Western blotting.

### Claim 7 (depends on 1)

The method of claim 1, wherein the ability of the test compound to reduce osteopontin production is determined by RT-PCR.

### Claim 8 (depends on 1)

The method of claim 1, wherein the ability of the test compound to reduce osteopontin production is determined by northern blotting.

### Claim 9 (depends on 1)

The method of claim 1, wherein said test compound which reduces osteopontin level is selected based on its ability to reduce bone pain in a subject having myeloma.

### Claim 10 (depends on 1)

The method of claim 1, wherein said test compound which reduces osteopontin level is selected based on its ability to reduce the number of osteoclastic bone-resorbing lesions in a subject having myeloma.